Cargando…

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Stehle, Daniel, Xu, Min Ze, Schomber, Tibor, Hahn, Michael G., Schweda, Frank, Feil, Susanne, Kraehling, Jan R., Eitner, Frank, Patzak, Andreas, Sandner, Peter, Feil, Robert, Bénardeau, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292672/
https://www.ncbi.nlm.nih.gov/pubmed/34096053
http://dx.doi.org/10.1111/bph.15586
_version_ 1784749427394609152
author Stehle, Daniel
Xu, Min Ze
Schomber, Tibor
Hahn, Michael G.
Schweda, Frank
Feil, Susanne
Kraehling, Jan R.
Eitner, Frank
Patzak, Andreas
Sandner, Peter
Feil, Robert
Bénardeau, Agnès
author_facet Stehle, Daniel
Xu, Min Ze
Schomber, Tibor
Hahn, Michael G.
Schweda, Frank
Feil, Susanne
Kraehling, Jan R.
Eitner, Frank
Patzak, Andreas
Sandner, Peter
Feil, Robert
Bénardeau, Agnès
author_sort Stehle, Daniel
collection PubMed
description BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, apo‐sGC. Apo‐sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. We hypothesised that sGC activators, which activate apo‐sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function. EXPERIMENTAL APPROACH: Two novel sGC activators, runcaciguat and BAY‐543, were tested on murine kidney. We measured cGMP levels in real time in kidney slices of cGMP sensor mice, vasodilation of pre‐constricted glomerular arterioles and RBF in isolated perfused kidneys. Experiments were performed at baseline conditions, under L‐NAME‐induced NO deficiency, and in the presence of oxidative stress induced by ODQ. KEY RESULTS: Mouse glomeruli showed NO‐induced cGMP increases. Under baseline conditions, sGC activator did not alter glomerular cGMP concentration or NO‐induced cGMP generation. In the presence of ODQ, NO‐induced glomerular cGMP signals were markedly reduced, whereas sGC activator induced strong cGMP increases. L‐NAME and ODQ pretreated isolated glomerular arterioles were strongly dilated by sGC activator. sGC activator also increased cGMP and RBF in ODQ‐perfused kidneys. CONCLUSION AND IMPLICATION: sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease‐relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc
format Online
Article
Text
id pubmed-9292672
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92926722022-07-20 Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney Stehle, Daniel Xu, Min Ze Schomber, Tibor Hahn, Michael G. Schweda, Frank Feil, Susanne Kraehling, Jan R. Eitner, Frank Patzak, Andreas Sandner, Peter Feil, Robert Bénardeau, Agnès Br J Pharmacol Cgmp Signalling in Cell Growth and Survival ‐ Research Papers BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, apo‐sGC. Apo‐sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. We hypothesised that sGC activators, which activate apo‐sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function. EXPERIMENTAL APPROACH: Two novel sGC activators, runcaciguat and BAY‐543, were tested on murine kidney. We measured cGMP levels in real time in kidney slices of cGMP sensor mice, vasodilation of pre‐constricted glomerular arterioles and RBF in isolated perfused kidneys. Experiments were performed at baseline conditions, under L‐NAME‐induced NO deficiency, and in the presence of oxidative stress induced by ODQ. KEY RESULTS: Mouse glomeruli showed NO‐induced cGMP increases. Under baseline conditions, sGC activator did not alter glomerular cGMP concentration or NO‐induced cGMP generation. In the presence of ODQ, NO‐induced glomerular cGMP signals were markedly reduced, whereas sGC activator induced strong cGMP increases. L‐NAME and ODQ pretreated isolated glomerular arterioles were strongly dilated by sGC activator. sGC activator also increased cGMP and RBF in ODQ‐perfused kidneys. CONCLUSION AND IMPLICATION: sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease‐relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc John Wiley and Sons Inc. 2021-07-03 2022-06 /pmc/articles/PMC9292672/ /pubmed/34096053 http://dx.doi.org/10.1111/bph.15586 Text en © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Cgmp Signalling in Cell Growth and Survival ‐ Research Papers
Stehle, Daniel
Xu, Min Ze
Schomber, Tibor
Hahn, Michael G.
Schweda, Frank
Feil, Susanne
Kraehling, Jan R.
Eitner, Frank
Patzak, Andreas
Sandner, Peter
Feil, Robert
Bénardeau, Agnès
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title_full Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title_fullStr Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title_full_unstemmed Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title_short Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
title_sort novel soluble guanylyl cyclase activators increase glomerular cgmp, induce vasodilation and improve blood flow in the murine kidney
topic Cgmp Signalling in Cell Growth and Survival ‐ Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292672/
https://www.ncbi.nlm.nih.gov/pubmed/34096053
http://dx.doi.org/10.1111/bph.15586
work_keys_str_mv AT stehledaniel novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT xuminze novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT schombertibor novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT hahnmichaelg novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT schwedafrank novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT feilsusanne novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT kraehlingjanr novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT eitnerfrank novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT patzakandreas novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT sandnerpeter novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT feilrobert novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney
AT benardeauagnes novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney